Rare Disease Manufacturing Platforms

Overview

A strategy for achieving manufacturing scale in rare disease therapeutics by identifying common platform technologies (lentiviral vectors, lipid nanoparticles) shared across individually small patient populations, enabling shared economics and regulatory prior-knowledge reuse across programs. While individual rare diseases each affect small patient populations, the aggregate of rare disease programs shares manufacturing platforms — all therapies using lentiviral vectors or all using lipid nanoparticles — creating a basis for aggregated scale and economic viability that Matthew Dy argues the industry must build on to serve patients cost-effectively. The 'Baby KJ' case — a successful but exceptional personalized gene therapy treatment — is cited by Matthew Dy as the exemplar that rare disease manufacturing platforms must make routine rather than a one-off experiment, requiring systematic changes to how the industry organizes itself rather than heroic individual efforts. (Segment 3 (10:00-15:00))